Cintia Ghoorchian
About Cintia Ghoorchian
Cintia Ghoorchian is a Cell Therapy Specialist III Lead at Kite Pharma, where she has worked since 2019. She holds an MBA from Golden Gate University and has a background in Biotechnology and Chemistry from California State University, Northridge.
Work at Kite Pharma
Cintia Ghoorchian has served as a Cell Therapy Specialist III Lead at Kite Pharma since 2019. In this role, she has contributed to the development and optimization of cell therapy manufacturing processes. Ghoorchian has played a key role in implementing quality control measures for cell therapy products, ensuring that they meet industry standards. Additionally, she has participated in cross-functional teams aimed at enhancing the efficiency of cell therapy operations, which has been crucial in scaling up production to meet increasing demand.
Education and Expertise
Cintia Ghoorchian is pursuing a Master of Business Administration (MBA) at Golden Gate University, which she began in 2021. She holds a Bachelor of Science in Biotechnology from California State University, Northridge, where she studied from 2016 to 2018. Additionally, she has a Bachelor of Science Minor in Chemistry from the same institution. This educational background has equipped her with the necessary knowledge and skills to excel in the field of cell therapy.
Previous Work Experience
Before her current role at Kite Pharma, Cintia Ghoorchian gained diverse experience in various positions. She worked as a Teaching Assistant at Kumon North America, Inc. from 2014 to 2019, where she developed skills in education and student support. She also served as a Chiropractic Assistant at Broadway Chiropractic Center, Inc. for seven months in 2016-2017. Additionally, she worked as a Pharmacy Clerk at Remedy Pharmacy for six months in 2018-2019, further broadening her experience in healthcare.
Contributions to Cell Therapy
Cintia Ghoorchian has made significant contributions to the field of cell therapy during her tenure at Kite Pharma. She has been involved in scaling up cell therapy production to meet the growing demand. Her participation in cross-functional teams has enhanced operational efficiency, and her role in implementing quality control measures has ensured the reliability of cell therapy products. These efforts reflect her commitment to advancing cell therapy manufacturing processes.